Azithromycin compared with amoxicillin in the treatment of erythema migrans: A double-blind, randomized, controlled trial

Annals of Internal Medicine

Volumn 124, Issue 9, 1996, Pages 785-791

  Luft, Benjamin J ^a   Dattwyler, Raymond J ^a   Johnson, Russell C ^b   Luger, Steven W ^c   Bosler, Elizabeth M ^a   Rahn, Daniel W ^d   Masters, Edwin J ^e   Grunwaldt, Edgar ^c   Gadgil, Shrikant D ^f  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Medical College of Georgia ^*  (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e Family Physicians Group Inc   (United States)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ERYTHEMA CHRONICUM MIGRANS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LYME DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SCHOOL CHILD; TREATMENT OUTCOME;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; AZITHROMYCIN; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HUMANS; MALE; PENICILLINS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT FAILURE;

EID: 0029968337     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-9-199605010-00002     Document Type: Article

References (20)

1. Lyme disease - United States, 1991-1992 MMWR Morb Mortal Wkly Rep 1993,42,345-8
2. Berger BW. Treatment of erythema chronicum migrans of Lyrne disease Ann N Y Acad Sci 1988;539:346-51
3. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis Lancet 1990;336 1404-6
4. Rahn DW, Malawista SE. Lyrne disease, recommendations for diagnosis and treatment Ann Intern Med 1991,114 472-81
5. Weber K, Neubert U, Thurmayr R. Antibiotic therapy in early erythema migrans disease and elated disorders. Zentralbl Bakteriol Mikrobiol Hyg [A] 1987;263 377-88
6. Preac-Mursic V, Wilske B, Schierz G, Suss E, Gross B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorfen Eur J Clin Microbiol Infect Dis 1989,8:651-3
7. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong RB, Johnson RC, et al. Treatment of early Lyme disease Am J Med 1992,92 396-403
8. Engstrom SM, Shoop E, Johnson RC. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease J Clin Microbiol 1995,33:419-27
9. Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin J Antimicrob Chemother. 1992,30.543-50
10. Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings Infection 1993,21 83-8
11. Luft BJ, Gorevic PD, Halperin JJ, Volkman DJ, Dattwyler RJ. A perspective on the treatment of Lyme borreliosis Rev Infect Dis 1989,11(Suppl 6): S1518-25
12. Feir D, Santanello CR, Li BW, Xie CS, Masters E, Marconi R, et al. Evidence supporting the presence of Borrelia burgdorfen in Missouri Am J Trop Med Hyg 1994;51.475-82
13. Boerlin P, Peter O, Bretz AG, Postic D, Baranton G, Piffaretti JC. Population genetic analysis of Borrelia burgdorfen isolates by multilocus enzyme electrophoresis Infect Immunol 1992,60 1677-83
14. Baranton G, Postic D, Saint Girons I, Boerlin P, Piffaretti JC, Assous M, et al. Delineation of Borrelia burgdorfen sensu strieto, Borrelia garinii sp nov , and group VS461 associated with Lyme borreliosis Int J Syst Bactenol. 1992,42 378-83.
15. Wallich R, Helmes C, Schaible UE, Lobet Y, Moter SE, Kramer MD, et al. Evaluation of genetic divergence among Borrelia burgdorferi isolates by use of OspA, f1a, Hsp60, and Hsp70 gene probes Infect Immunol. 1992,60 4856-66
16. Dykhuizen DE, Polin DS, Dunn JJ, Wilske B, Preac-Mursic V, Dattwyler RJ, et al. Borrelia burgdorferi is clonal implications for taxonomy and vaccine development Proc Natl Acad Sci U S A 1993,90.10163-7
17. Luft BJ, Steinman CR, Neimark HC, Muralidhar B, Rush T, Finkel MF, et al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA 1992,267 1364-7
18. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease Ann Interm Med 1992,117 273-80
19. Treatment of Lyme disease Med Lett Drug Ther 1992,34 95-7.
20. Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorfen. N Engl J Med 1988;319 1441-6